Akero Therapeutics Inc (STU:0K4)

€ 28.54 -0.79 (-2.69%) Market Cap: 2.03 Bil Enterprise Value: 1.38 Bil PE Ratio: 0 PB Ratio: 2.89 GF Score: 34/100

Akero Therapeutics Inc at JPMorgan Healthcare Conference Transcript
Jan 08, 2024
Akero Therapeutics Inc Phase 2b SYMMETRY Data Presentation Transcript
Oct 10, 2023
Akero Therapeutics Inc at Morgan Stanley Global Healthcare Conference Transcript
Sep 12, 2023
Akero Therapeutics Inc Phase 2b SYMMETRY Cohort D Data Presentation Transcript
Jun 05, 2023
Akero Therapeutics Inc at JPMorgan Healthcare Conference Transcript
Jan 10, 2023
Akero Therapeutics Inc at H C Wainwright NASH Investor Conference (Virtual) Transcript
Oct 17, 2022
Akero Therapeutics Inc Phase 2B HARMONY Trial Data Presentation Transcript
Sep 13, 2022
Akero Therapeutics Inc Annual Shareholders Meeting Transcript
Jun 02, 2022
Akero Therapeutics Inc at Bank of America Healthcare Conference Transcript
May 11, 2022
Akero Therapeutics Inc at H C Wainwright NASH Investor Conference (Virtual) Transcript
Oct 12, 2021
Akero Therapeutics Inc at Credit Suisse Healthcare Conference (Virtual) Transcript
Nov 09, 2020

Akero Therapeutics Inc at JPMorgan Healthcare Conference Transcript

Jan 10, 2023 / 06:30PM GMT

Release Date Price: €40.6 (-3.33%)

Transcript

Eric William Joseph

JPMorgan Chase & Co, Research Division - VP & Senior Analyst

Good morning. I'm Eric Joseph, senior biotech analyst with JPMorgan. Our next presenting company is Akero Therapeutics, and presenting on behalf of the company is CEO, Andrew Cheng.

There will be a Q&A after the presentation. Just raise your hand, and we'll get you a microphone. And for those folks tuning in online, you can submit a question via the digital conference (inaudible). So with that, Andrew, thank you.

Andrew Cheng

Akero Therapeutics, Inc. - President, CEO & Director

Good morning, and thank you, Eric.

So it's my pleasure to be here at -- in person at the '23 JPMorgan Healthcare Conference. And so why don't we go ahead and get started. So this is our safe harbor statement, of course, given the font size, I won't be reading that nor do you want to hear that. So I think we can -- now that it's been on the screen, we can move to the next slide.

So when we look at our corporate highlights and we think about what's happened in

Already have an account? Log in

Get the full story

Start 7-Day Free Trial

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

30-Day 100% money back guarantee

You are not charged until the trial ends. Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Mobile App 中文

Education

Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.